CardioValve’s solution allows the replacement of regurgitating mitral and tricuspid valves using a safer minimally invasive technique. This solution improves patients’ quality of life by replacing costly open-heart surgeries and assists in avoiding unnecessary hospitalizations which risk the lives of hundreds of millions of patients around the world. Co-Founded in Or Yehuda, in 2017 as a spin-off of Valtech Cardio (acquired by Edwards Lifesciences), one of Peregrine Ventures’ early-stage investments.
Menu
